To include your compound in the COVID-19 Resource Center, submit it here.

Genentech, CDER post Avastin questions

Genentech Inc. and FDA's Center for Drug Evaluation and Research submitted summaries of what each considers the central questions to be presented and resolved at a June 28-29 hearing on

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE